Eli Lilly (LLY)

1,146.90
-32.21 (-2.73%)
NYSE· Last Trade: Jul 20th, 7:39 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1,179.11
Open1,179.65
Bid1,146.55
Ask1,150.00
Day's Range1,144.43 - 1,187.12
52 Week Range623.78 - 1,249.45
Volume2,643,905
Market Cap1.10T
PE Ratio (TTM)49.97
EPS (TTM)22.9
Dividend & Yield6.920 (0.60%)
1 Month Average Volume3,029,728

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Now That Eli Lilly Trades Above $1,000, Is a Stock Split Finally on the Table?fool.com
Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.
Via The Motley Fool · July 20, 2026
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?fool.com
Beam Therapeutics' growing pipeline could reward patient investors.
Via The Motley Fool · July 20, 2026
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?fool.com
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
Via The Motley Fool · July 20, 2026
Eli Lilly & Co. (NYSE:LLY) Stands Out With High Growth Momentum and a Breakout Setupchartmill.com
Via Chartmill · July 17, 2026
Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?fool.com
IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.
Via The Motley Fool · July 20, 2026
PJP vs. IYH: Which Healthcare ETF Is the Better Buy?fool.com
PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.
Via The Motley Fool · July 20, 2026
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?fool.com
It is definitely a strong contender.
Via The Motley Fool · July 20, 2026
Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Yearsfool.com
Maybe you should, too.
Via The Motley Fool · July 19, 2026
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?fool.com
BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.
Via The Motley Fool · July 19, 2026
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?fool.com
IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance?
Via The Motley Fool · July 18, 2026
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1fool.com
Viking's latest program seeks to push the envelope in weight loss efficacy.
Via The Motley Fool · July 18, 2026
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy?fool.com
IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.
Via The Motley Fool · July 18, 2026
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Lossfool.com
There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.
Via The Motley Fool · July 17, 2026
Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Winfool.com
Novo Nordisk is finally getting one up on its biggest rival.
Via The Motley Fool · July 17, 2026
Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion Considers Strategic Alternativesbenzinga.com
Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are happening.
Via Benzinga · July 17, 2026
Why AtaiBeckley Stock Soared Todayfool.com
The psychedelic drugmaker is being acquired.
Via The Motley Fool · July 16, 2026
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billionfool.com
Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.
Via The Motley Fool · July 16, 2026
This GLP-1 Stock Could Double by 2030. Here's Whyfool.com
Investors need to ask tough questions before initiating a position in this biotech company.
Via The Motley Fool · July 16, 2026
Why Is GH Research Stock Trading Higher on Thursday?benzinga.com
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.
Via Benzinga · July 16, 2026
AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Dealbenzinga.com
Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.
Via Benzinga · July 16, 2026
Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026?fool.com
One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.
Via The Motley Fool · July 16, 2026
Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETFfool.com
IXJ's market-cap weighting and international exposure delivered stronger five-year returns and lower volatility, while offering double the dividend yield.
Via The Motley Fool · July 16, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
BALA CYNWYD, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · July 16, 2026
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH?fool.com
IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.
Via The Motley Fool · July 16, 2026
Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeoverinvestors.com
Eli Lilly tripped into the psychedelics space Thursday with the up to $3.8 billion acquisition of AtaiBeckley.
Via Investor's Business Daily · July 16, 2026